ARA-290 16 MG

ARA-290 16 mg – Peptide Hubs

ARA-290 is a synthetic peptide derivative of erythropoietin (EPO) engineered for tissue protection without affecting red blood cell production. The 16 mg lyophilized vial from Peptide Hubs offers researchers a powerful tool for studying neuropathic pain, inflammation modulation, and autoimmune disorders without the hematopoietic effects of full-length EPO.

What Is ARA-290?

ARA-290 is an 11-amino-acid peptide developed to selectively activate the innate repair receptor (IRR), which plays a role in tissue protection and anti-inflammatory responses. It has shown promise in preclinical studies for reducing chronic pain, improving insulin sensitivity, and modulating immune response in conditions such as sarcoidosis, small fiber neuropathy, and diabetes-related nerve damage.

Mechanism of Action

Unlike erythropoietin, which activates both EPOR and IRR, ARA-290 binds exclusively to the IRR. This avoids the red blood cell–producing side effects of EPO while retaining its beneficial effects on damaged tissues. It is currently being studied for its ability to reduce oxidative stress, inflammation, and nerve pain in both animal and human clinical trials. For a detailed molecular breakdown, refer to this NIH publication on ARA-290.

Applications in Research

ARA-290 is gaining popularity in neuroscience, diabetes, and inflammatory condition research due to its neuroprotective and regenerative potential. Bodybuilders and biohackers also express interest in ARA-290 for its off-label anti-inflammatory effects post-cycle, especially when combined with agents like BPC-157 or GHK-CU.

Suggested Experimental Use

• Dose: 4–8 mg per day
• Administration: Subcutaneously, usually in morning or post-activity
• Cycle: 5–20 days depending on research protocol

Researchers sometimes administer ARA-290 alongside Semax for cognitive or neurogenic support in central nervous system–related studies.

Stacking Options

To enhance regenerative pathways and reduce systemic inflammation, ARA-290 is commonly stacked with:

• BPC-157 – tissue and gut repair
• Melanotan II – improved skin resilience and photo-protection
• AOD 9604 – for metabolic regulation

Side Effects and Safety

ARA-290 has a low risk profile. Studies show no elevation in hematocrit or hemoglobin, which is a common concern with full-length EPO. Mild injection site irritation and rare fatigue are reported in some cases. It does not affect hormonal pathways, liver enzymes, or cause water retention or androgenic side effects.

Legal Disclaimer

ARA-290 is sold strictly for laboratory and research purposes. It is not approved by the FDA for human consumption. Usage must comply with research-only guidelines. For information on WADA status and potential clinical trial data, visit the ClinicalTrials.gov database.

Frequently Asked Questions